1. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040.
- Author
-
El-Khoueiry, A.B., Trojan, J., Meyer, T., Yau, T., Melero, I., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Kang, Y.-K., Yeo, W., Chopra, A., Soleymani, S., Yao, J., Neely, J., Tschaika, M., Welling, T.H., and Sangro, B.
- Subjects
- *
NIVOLUMAB , *ADVERSE health care events , *HEPATOCELLULAR carcinoma - Abstract
Patients with advanced hepatocellular carcinoma (aHCC) have a poor prognosis and high mortality. Nivolumab monotherapy demonstrated clinical benefit with an acceptable safety profile in patients with aHCC in the CheckMate 040 study. Five-year follow-up of the sorafenib-naive and sorafenib-experienced groups of CheckMate 040 is presented here. Patients received nivolumab monotherapy at dose levels of 0.1-10.0 mg/kg (dose-escalation phase) or 3 mg/kg (dose-expansion phase) every 2 weeks until disease progression or unacceptable toxicity. Primary endpoints were safety and tolerability (dose escalation), and objective response rate (ORR) by blinded independent central review (BICR) and by investigator as per RECIST version 1.1 (dose expansion). Eighty sorafenib-naive and 154 sorafenib-experienced patients were treated. Minimum follow-up in both groups was 60 months. ORR as per BICR was 20% [95% confidence interval (CI) 12% to 30%] and 14% (95% CI 9% to 21%) in the sorafenib-naive and sorafenib-experienced groups, respectively. Responses occurred regardless of HCC etiology or baseline tumor cell programmed death-ligand 1 (PD-L1) expression levels. Median overall survival (OS) was 26.6 months (95% CI 16.6-30.6 months) and 15.1 months (95% CI 13.0-18.2 months) in sorafenib-naive and sorafenib-experienced patients, respectively. The 3-year OS rates were 28% in the sorafenib-naive and 20% in the sorafenib-experienced groups; 5-year OS rates were 14% and 12%, respectively. No new safety signals were identified; grade 3/4 treatment-related adverse events were observed in 33% and 21% of patients in the sorafenib-naive and sorafenib-experienced groups, respectively. Biomarker analyses showed that baseline PD-L1 expression ≥1% was associated with higher ORR and longer OS compared with PD-L1 <1%. In the sorafenib-naive group, patients with OS ≥3 years exhibited higher baseline CD8 T-cell density compared with those with OS <1 year. With 5 years of follow-up, nivolumab monotherapy continued to provide durable clinical benefit with manageable safety in sorafenib-naive and sorafenib-experienced patients with aHCC. • At 5 years of follow-up, nivolumab monotherapy continued to provide durable clinical benefit in patients with aHCC. • ORR was 20% in the sorafenib (SOR)-naive group and 14% in the SOR-experienced group. • 3-year OS rates were 28% in the SOR-naive and 20% in the SOR-experienced groups; 5-year rates were 14% and 12%, respectively. • The safety profile of nivolumab monotherapy was manageable and no new safety signals were identified. • Higher ORR and longer OS were noted with baseline PD-L1 ≥1% versus <1% and were more prominent in the SOR-experienced group. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF